Overview

Study of BHV-4157 in Alzheimer's Disease

Status:
Active, not recruiting

Trial end date:
2022-01-23

Target enrollment:

Participant gender:

Summary

Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, taken orally once daily. Duration of treatment is 48 weeks. There is also a screening period of up to 42 days; and a 4-week post-treatment observation period.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Biohaven Pharmaceuticals, Inc.

Collaborator:

Alzheimer's Disease Cooperative Study (ADCS)